Hogan Lovells Publications
Digital health solutions in Germany: Detailed requirements for eligibility to reimbursement being fleshed out in draft legislation
25 February 2020
AssociateMunich
Email benjamin.goehl@hoganlovells.com
Phone +49 89 290 12 0
LanguagesGerman, English
Practice groupGlobal Regulatory
Benjamin Goehl advises on all kinds of commercial and regulatory matters of our national and international clients in the pharmaceutical, medical devices and biotech industry.
Benjamin's work focuses on regulatory advice in pharmaceutical and medical device law, drafting contracts for the cooperation of different stakeholders in the health care sector and advising in health care advertising matters, in particular regarding promotional materials for pharmaceuticals and rebate schemes. Benjamin also advises on compliance issues in cooperation with health care professionals. He is particularly interested in regulatory and reimbursement aspects of innovative digital health solutions.
Benjamin already focused on medical law during his studies. He worked as a research associate in the field of medical law and wrote a thesis on liability for medical malpractice. During his legal traineeship, he worked, inter alia, for our product liability practice, where he focused on pharmaceutical and medical devices matters. Benjamin also worked in our London office as a legal trainee.
Education
Second State Exam in Law, Higher Regional Court of Munich, 2019
Dr. iur., LMU Munich (Ludwig-Maximilians-Universität München), 2018
First State Exam in Law, University of Göttingen, 2014
Advising an international medical devices company on rebate designs.
Advising an international pharmaceutical company on regulatory aspects of their cooperation with a manufacturer of a digital health solution.
Advising a provider of digital health services on reimbursement for a digital health solution in Germany.
Advising an international pharmaceutical company on compliance requirements for their cooperation agreements with HCPs.
Advising an international pharmaceutical company on its contractual relationship with its distribution partners.
Advice on COVID-19 related matters, e.g. manufacturing of ventilators and manufacturing/import of face masks/face shields.